Treatment value of second-generation BCR-ABL1 tyrosine kinase inhibitors compared with imatinib to achieve treatment-free remission in patients with chronic myeloid leukaemia: a modelling study-Reference-Cited by-同舟云学术

Treatment value of second-generation BCR-ABL1 tyrosine kinase inhibitors compared with imatinib to achieve treatment-free remission in patients with chronic myeloid leukaemia: a modelling study

Published:2019-08 Issue:8 Volume:6 Page:e398-e408
ISSN:2352-3026
Container-title:The Lancet Haematology
language:en
Short-container-title:The Lancet Haematology

Author:

Shih Ya-Chen Tina,Cortes Jorge E,Kantarjian Hagop M

Publisher

Elsevier BV

Subject

Hematology

Reference26 articles.

1. Chronic myeloid leukemia;Kantarjian,2018

2. Chronic myeloid leukemia;Kantarjian,2013

3. Generic imatinib-impact on frontline and salvage therapy for CML;Gorkin;Clin Oncol,2016

4. Having ‘skin in the game’ and allowing cross-border importation of drugs to lower high prices of cancer drugs;Kantarjian;JAMA Oncol,2015

Cited by 49 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Choosing the Best Firstline Drug: Does Efficacy Make You Think About Cost?;Clinical Lymphoma Myeloma and Leukemia;2024-09

2. [Artículo traducido] Asciminib para el tratamiento de la leucemia mieloide crónica en tercera línea: análisis coste-efectividad basado en el enfoque de remisión libre de tratamiento;Farmacia Hospitalaria;2024-09

3. Asciminib for third-line treatment of chronic myeloid leukemia: Cost-effectiveness analysis based on treatment-free remission approach;Farmacia Hospitalaria;2024-09

4. Optimal frontline therapy of chronic myeloid leukemia today, and related musings;American Journal of Hematology;2024-08-02

5. Chronic myeloid leukemia: 2025 update on diagnosis, therapy, and monitoring;American Journal of Hematology;2024-08-02